1700 El Camino Real
40 articles with IncellDx
Company launches www.covidlonghaulers.com website to facilitate immune profiling and therapy
IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer's FDA-approved CCR5 antagonist Maraviroc.
IncellDx, Inc., a global leader in single-cell diagnostics, announces the USPTO has issued patent US10,782,298 to IncellDx.
IncellDx and MD Biosciences Sign Definitive Agreement for Commercialization of COVID-19/Cytokine Storm Cytokine Panel and CCR5 Receptor Occupancy in US and EU
IncellDx, Inc., a global leader in single-cell diagnostics, announces the signing of an agreement with MD Biosciences, Inc. for the commercialization of novel assays based on IncellDx's work on diagnostic, prognostic, and therapeutic biomarkers in COVID-19 and other cytokine storm conditions. Under the terms of the agreem
Factorial Diagnostics, IncellDx Sign Exclusive License for Novel in situ Library Prep for Subsequent Next Generation DNA Sequencing
Factorial Diagnostics and IncellDx announced that they have agreed to terms on an exclusive license and supply agreement for technology that will enable the development of their multi-omic, cancer diagnostic workflow.
IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions
Company files Pre-EUA with FDA for CCR5 Receptor Occupancy and COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES
IncellDx’s Next Gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) Receives Clinical Approval from Costa Rican Ministry of Health
IncellDx, Inc., a global leader in single-cell diagnostics, announces approval by the Costa Rican Ministry of Health of its Next Generation HPV/cervical cancer assay, OncoTect 3Dx. This novel assay is the only test to simultaneously detect and quantify 3 molecular markers of cervical cancer—overexpression of oncogenes (E6, E7 mRNA), proliferation, and aneuploidy
IncellDx, Inc. and Biolidics have announced that they have signed a Distribution Agreement for the IncellDx bioINK® PD-L1 CTC Core Kit. Biolidics will distribute the product with the Biolidics' ClearCell® FX1 System.
IncellDx Awarded Patent for Blood Collection Tube (BCT) That Activates HIV from Latent Cellular Reservoirs in the Tube
IncellDx, a leading single cell cancer diagnostics company, announced the issuing of a US patent for a blood collection tube that stimulates dormant HIV to produce virus in the infected cells while in the blood collection tube.
IncellDx today announced it has entered into an assay development agreement with Zomedica to identify and enumerate circulating tumor cells (CTCs) from canine cancers using its BioINK Liquid Biopsy Reagent Platform.
IncellDx Launches BioINK PD-L1 CTC Core Kit with Lyophilized CTC Control Cells for Microfluidic Liquid Biopsies
IncellDx has launched a complete, pre-optimized kit to identify, enumerate, and quantify the important tumor therapeutic target PD-L1 on circulating tumor cells (CTCs).
The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry.
Celsee and IncellDx Sign Co-Commercialization Agreement Following Successful Lung Cancer/CTC PD-L1 Feasibility Study
The statistically-significant feasibility study analyzed PD-L1 expression in paired lung tumor biopsy and peripheral blood specimens using two different molecular analysis technologies, the IncellDx OncoTect iO Single Cell Quantitative PD-L1 assay and the Celsee C-Prep Genesis.
GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company.
GIMDx and IncellDx Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in China
GIMDx announced today that it has concluded an exclusive OEM and International Distribution agreement for IncellDx single cell immune-oncology and oncology diagnostic products in China.
Beckman Coulter, Inc. And IncellDx, Inc. Sign Distribution Partnership To Benefit Human Papilloma Virus (HPV) Research In China, Hong Kong And Taiwan
IncellDx, Inc. Signs Exclusive License With Claremont BioSolutions To Commercialize Novel Liquid-Based Biopsy Technology
MD Anderson Cancer Center And PPRI In Early Stage Breast Cancer Studies With IncellDx, Inc. Oncobreast3Dx® Technology